There is little evidence that @entity683 vaccination reduces @entity565 exacerbations. We determined whether @entity683 vaccination is more effective than placebo in 6-18-year-old @entity1 with @entity565 . We performed a randomized, double-blind, placebo-controlled trial. Parenteral vaccination with inactivated @entity683 vaccine or placebo took place approximately November 1, and @entity1 were followed until April 1 of the next year. Airway symptoms were reported in a diary. When symptom scores reached a predefined level, a pharyngeal swab was taken. Primary outcome was the number of @entity565 exacerbations associated with virologically proven @entity281 . Three hundred forty-nine @entity1 were assigned placebo, and 347 were assigned vaccine. Pharyngeal swabs positive for @entity683 were related to 42 @entity565 exacerbations, 24 in the vaccine group and 18 in the placebo group, a difference of 33% favoring placebo (31% after adjustment for confounders; 95% confidence interval, -34% to 161%). Influenza-related @entity565 exacerbations were of similar severity in both groups; they lasted 3.1 days shorter in the vaccine group (95% confidence interval, -6.2 to 0.002 days, p = 0.06). We conclude that @entity683 vaccination did not result in a significant reduction of the number, severity, or duration of @entity565 exacerbations caused by @entity683 . Additional studies are warranted to justify routine @entity683 vaccination of @entity1 with @entity565 .

Influenza vaccination in @entity1 with XXXX : randomized double-blind placebo-controlled trial.

@entity1 :: ('9606', 'Species') :: ['children'] @entity683 :: ('MESH:D007251', 'Disease') :: ['influenza'] @entity281 :: ('MESH:D007239', 'Disease') :: ['influenza infection'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma']
@entity565 :: (MESH:D001249,Disease) :: ['asthma']
